Prognosis of medullary breast cancer: Analyses of 13 International Breast Cancer Study Group (IBCSG) trials.

Huober, Jens; Gelber, S.; Thurlimann, B.; Regan, Meredith M.; Price, KN; Goldhirsch, Aron; Coates, A. S.; Viale, G.; Oehlschlegel, Christian

doi:10.1200/jco.2010.28.15_suppl.630

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 66 Good outcomes (14-year distant recurrence-free interval of 89% for ER-negative medullary breast cancer) were also noticed in the International Breast Cancer Study Group (IBCSG) (n = 127), but almost 70% received adjuvant chemotherapy. 67 High-grade metaplastic carcinomas may be resistant to systemic cytotoxic therapy and are associated with poor prognosis while low-grade metaplastic breast cancers may have better prognosis (ie, fibromatosis-like carcinoma). 68 , 69 …”

Section: Clinical and Pathological Presentationmentioning

confidence: 99%

Update on triple-negative breast cancer: prognosis and management strategies

Brouckaert¹,

Wildiers²,

Floris³

et al. 2012

IJWH

View full text Add to dashboard Cite

Triple negative breast cancer (TNBC) is a heterogeneous disease comprehending different orphan breast cancers simply defined by the absence of ER/PR/HER-2. Approximately 15%–20% of all breast cancers belong to this phenotype that has distinct risk factors, distinct molecular features, and a particular clinical presentation and outcome. All these features will be discussed in this review. The risk of developing TNBC varies with age, race, genetics, breastfeeding patterns, and parity. Some TNBC are very chemo-sensitive and the majority of patients confronted with and treated for TNBC will never relapse. Some (histological) subgroups of TNBC may have good prognosis even in the absence of chemotherapy. Distinct molecular subgroups within TNBC have been defined now as well. In case metastatic relapse occurs, this is usually within 5 years following surgery, and survival following metastatic relapse is shorter compared to other breast cancer subtypes; treatment options are few and responses lack durability. Novel drug targets and new biomarkers are needed to improve breast cancer care for patients presenting with TNBC. Further molecular/biological unraveling of TNBC is needed.

show abstract

Section: Clinical and Pathological Presentationmentioning

confidence: 99%

Update on triple-negative breast cancer: prognosis and management strategies

Brouckaert¹,

Wildiers²,

Floris³

et al. 2012

IJWH

View full text Add to dashboard Cite

show abstract

“…The majority of TNBC are high grade ductal carcinoma but less common specific type (metaplastic, medullary and adenoid cystic carcinomas). However, caution should be used when stratifying risk among patients with TNBC with special histologic subtypes because tumor types such as classical defined medullary carcinoma and adenoid cystic carcinoma have an inherently favorable prognosis despite being classified as TNBCs (23)(24)(25)(26)(27). Using the transriptome data set from 21 independent breast cancer studies identified different clusters de-fined by mesenchymal features, immune system-related genes, DNA damage response genes, and activated androgen receptor signaling.…”

Section: Diagnostic Featuresmentioning

confidence: 99%

Triple negative breast cancer: heterogenous disease

Scinto¹

2013

RIO

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) is a distinct subset of breast cancer defined by the lack of immunohistochemical expression of estrogen and progesterone receptors and epidermal growth factor receptor 2. It is a heterogeneous disease and displays overlapping characteristics with both basal-like and brca 1-2 BCs. This review evaluates the activity of emerging target agent in TNBC.KEY WORDS: triple negative breast cancer, basal-like, heterogeneous disease, metastatic breast cancer.

show abstract

Adjuvant systemic treatment for individual patients with triple negative breast cancer

Oakman¹,

Moretti²,

Galardi³

et al. 2011

The Breast

View full text Add to dashboard Cite

Chemotherapy is the only evidence based adjuvant systemic treatment option in triple negative breast cancer (TNBC). Despite emerging results for targeted biological therapies for this subpopulation, lack of robust results does not currently support their use beyond the confines of a clinical trial. Conventional systemic chemotherapy remains the standard of care and is curative in a minority of patients. There is no defined standard chemotherapy and there is currently no robust, prospective, randomized data to advise different use of specific chemotherapy agents in TNBC as compared to non-TNBC. Data suggest high sensitivity to chemotherapy, however it is yet to be determined whether this increased sensitivity is agent/regimen specific or whether it reflects general chemosensitivity. This review will focus on systemic chemotherapy in early TNBC, particularly anthracyclines and platinums, and potential predictive tools to guide chemotherapy use.

show abstract

Prognosis of medullary breast cancer: Analyses of 13 International Breast Cancer Study Group (IBCSG) trials.

Cited by 4 publications

References 0 publications

Update on triple-negative breast cancer: prognosis and management strategies

Update on triple-negative breast cancer: prognosis and management strategies

Triple negative breast cancer: heterogenous disease

Adjuvant systemic treatment for individual patients with triple negative breast cancer

Contact Info

Product

Resources

About